Copyright
©The Author(s) 2000.
World J Gastroenterol. Dec 15, 2000; 6(6): 829-832
Published online Dec 15, 2000. doi: 10.3748/wjg.v6.i6.829
Published online Dec 15, 2000. doi: 10.3748/wjg.v6.i6.829
Table 6 Comparison between vaccine group and control group on HAV infection features
| Groups | No. of Subjects | IgM anti-HAV (+) | Clinical HA cases | Subclinical infection | Novel infection | Clinical/subclinical ratio | ||||
| No. | % | No. | % | No. | % | No. | % | |||
| Vaccine | 271 | 12 | 4.4 | 1 | 0.4 | 11 | 4.1 | 12 | 4.4 | 1:11 |
| Control | 314 | 39 | 12.4 | 21 | 6.7 | 21 | 6.7 | 42 | 13.4 | 1:1 |
| Relative risk | 2.8 | 18.1 | 1.7 | 3.0 | 6.0 | |||||
| 95%CI | 1.5-5.3 | 2.5-133.9 | 0.8-3.4 | 1.6-5.6 | 0.9-40.2 | |||||
| χ² | 11.7 | 16.0 | 1.9 | 13.9 | ||||||
| P value | < 0.001 | < 0.001 | > 0.5 | < 0.001 | < 0.01 | |||||
| Statistical method | M-H | M-H | M-H | M-H | Fisher | |||||
- Citation: Zhao YL, Meng ZD, Xu ZY, Guo JJ, Chai SA, Duo CG, Wang XY, Yao JF, Liu HB, Qi SX, Zhu HB. H2 strain attenuated live hepatitis A vaccines: Protective efficacy in a hepatitis A outbreak. World J Gastroenterol 2000; 6(6): 829-832
- URL: https://www.wjgnet.com/1007-9327/full/v6/i6/829.htm
- DOI: https://dx.doi.org/10.3748/wjg.v6.i6.829